Evidence map›Paper›PMID 36416305›Full record

ArticleHistopathology2023

Primary mucosal melanomas of the head and neck are characterised by overexpression of the DNA mutating enzyme APOBEC3B.

Prokopios P Argyris, Jordan Naumann, Matthew C Jarvis, Peter E Wilkinson, Dan P Ho, Mohammed N Islam, Indraneel Bhattacharyya, Rajaram Gopalakrishnan, Faqian Li, Ioannis G Koutlas and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Histopathology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Journal of virology · 2026
    Article
  3. bioRxiv : the preprint server for biology · 2025
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Human APOBEC3B promotes tumor heterogeneitybioRxiv : the preprint server for biology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Prokopios P ArgyrisDepartment of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, USA.ORCID https://orcid.org/0000-0002-5965-6181
Jordan NaumannDepartment of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, USA.
Matthew C JarvisDepartment of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, USA.
Peter E WilkinsonDepartment of Diagnostic and Biological Sciences, School of Dentistry, University of Minnesota, Minneapolis, MN, USA.
Dan P HoDepartment of Diagnostic and Biological Sciences, School of Dentistry, University of Minnesota, Minneapolis, MN, USA.
Mohammed N IslamDepartment of Oral and Maxillofacial Diagnostic Sciences, University of Florida College of Dentistry, Gainesville, FL, USA.
Indraneel BhattacharyyaDepartment of Oral and Maxillofacial Diagnostic Sciences, University of Florida College of Dentistry, Gainesville, FL, USA.
Rajaram GopalakrishnanDivision of Oral and Maxillofacial Pathology, School of Dentistry, University of Minnesota, Minneapolis, MN, USA.
Faqian LiDepartment of Laboratory Medicine and Pathology, Medical School, University of Minnesota, Minneapolis, MN, USA.
Ioannis G KoutlasDivision of Oral and Maxillofacial Pathology, School of Dentistry, University of Minnesota, Minneapolis, MN, USA.
Alessio GiubellinoDepartment of Laboratory Medicine and Pathology, Medical School, University of Minnesota, Minneapolis, MN, USA.ORCID https://orcid.org/0000-0002-5352-0662
Reuben S HarrisDepartment of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, USA.
University of Minnesota · USUniversity of Florida · USUniversity of Minnesota Medical Center · US

Funding

PROJECT 3 – BIOLOGY OF DNA DEAMINASES IN CANCERP01CA234228 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Reuben S Harris · 2019 to 2026
$14.5M
Training in PharmacoNeuroImmune Substance Abuse ResearchT32DA007097 · NIDA · UNIVERSITY OF MINNESOTA TWIN CITIES · PI MOLITOR, THOMAS WILLIAM · 1985 to 2021
$13.1M
TRAINING GRANT IN MICROBIOLOGY/CANCER RESEARCHT32CA009138 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Scott M. Dehm · 1985 to 2026
$11.3M
The APOBEC in APOBEC mutagenesisF31CA243306 · NCI · UNIVERSITY OF MINNESOTA · PI JARVIS, MATTHEW C · 2019 to 2021
$94k
Foundation for the National Institutes of Health F31-CA243306Foundation for the National Institutes of Health P01-CA234228Foundation for the National Institutes of Health T32-CA009138Foundation for the National Institutes of Health T32-DA007097NCI NIH HHS F31 CA243306NCI NIH HHS P01 CA234228NCI NIH HHS T32 CA009138NIDA NIH HHS T32 DA007097
6 · The paper itself

Abstract

aimsPrimary head/neck mucosal melanomas (MMs) are rare and exhibit aggressive biologic behaviour and elevated mutational loads. The molecular mechanisms responsible for high genomic instability observed in head/neck MMs remain elusive. The DNA cytosine deaminase APOBEC3B (A3B) constitutes a major endogenous source of mutation in human cancer. A3B-related mutations are identified through C-to-T/-G base substitutions in 5'-TCA/T motifs. Herein, we present immunohistochemical and genomic data supportive of a role for A3B in head/neck MMs. METHODS AND

resultsA3B protein levels were assessed in oral (n = 13) and sinonasal (n = 13) melanomas, and oral melanocytic nevi (n = 13) by immunohistochemistry using a custom rabbit α-A3B mAb (5210-87-13). Heterogeneous, selective-to-diffuse, nuclear only, A3B immunopositivity was observed in 12 of 13 (92.3%) oral melanomas (H-score range = 9-72, median = 40) and 8 of 13 (62%) sinonasal melanomas (H-score range = 1-110, median = 24). Two cases negative for A3B showed prominent cytoplasmic staining consistent with A3G. A3B protein levels were significantly higher in oral and sinonasal MMs than intraoral melanocytic nevi (P < 0.0001 and P = 0.0022, respectively), which were A3B-negative (H-score range = 1-8, median = 4). A3B levels, however, did not differ significantly between oral and sinonasal tumours (P > 0.99). NGS performed in 10 sinonasal MMs revealed missense NRAS mutations in 50% of the studied cases and one each KIT and HRAS mutations. Publicly available whole-genome sequencing (WGS) data disclosed that the number of C-to-T mutations and APOBEC3 enrichment score were markedly elevated in head/neck MMs (n = 2).

conclusionThe above data strongly indicate a possible role for the mutagenic enzyme A3B in head/neck melanomagenesis, but not benign melanocytic neoplasms.

Indexed as

MelanomaMouth NeoplasmsNevus, PigmentedParanasal Sinus NeoplasmsAnimalsCytidine DeaminaseHumansMinor Histocompatibility AntigensMutationRabbitsAPOBEC3B protein, humanCytidine DeaminaseMinor Histocompatibility AntigensAPOBEC3BAPOBEC3GDNA cytosine deaminationHRASKITNRASoral mucosal melanomasinonasal mucosal melanoma

Identifiers

PMID36416305
PMCPMC10107945
OpenAlexW4309765044

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.